{"id":78752,"date":"2023-10-31T01:48:40","date_gmt":"2023-10-31T05:48:40","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/drug-stocks-keep-falling-on-earnings-it-could-be-a-long-week\/"},"modified":"2023-10-31T01:48:45","modified_gmt":"2023-10-31T05:48:45","slug":"drug-stocks-keep-falling-on-earnings-it-could-be-a-long-week","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=78752","title":{"rendered":"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week."},"content":{"rendered":"
\n
<\/p>\n

<\/p>\n

<\/p>\n
<\/div>\n<\/figure><\/div>\n

Investors have been hating what drugmakers have to say about their financial results and their corporate strategies.<\/p>\n

When
\n Bristol Myers Squibb
\n (ticker: BMY) reported its third-quarter earnings on Thursday, shares ended the day down 3.6%, and fell another 2% on Friday.
\n AbbVie
\n stock (ABBV) fell 6.3% on Friday after that company reported earnings.<\/p>\n

\n

\n Merck
\n (MRK) shares climbed 1.9% on Thursday after its earnings report, but then more than gave up those gains on Friday, dropping 2.7%.
\n Johnson & Johnson
\n (JNJ), which reported its third-quarter earnings on Oct. 17, was setting new 52-week lows by Thursday.<\/p>\n

All of those drops were just bumps in the road compared with the rout in
\n Sanofi
\n (SNY) shares on Friday. The company reported earnings, with financial guidance that was lower than expected, while announcing plans to separate from its consumer-health division. The company\u2019s American depositary receipt dropped 19%, erasing more than $20 billion in market value.<\/p>\n

With most of the rest of the big pharma stocks set to report earnings by the end of the week, this is an uneasy moment for the sector. Investors have been lukewarm on pharmaceutical stocks for months. Before the open on Monday, the
\n S&P 500 Pharmaceuticals industry index
\n had dropped 7.2% this year, while the
\n S&P 500
\n was up 7.2%.<\/p>\n

The earnings selloffs seems a signal that the stocks aren\u2019t like to rebound soon, and should do away with any lingering illusions that pharma stocks represent a haven in an uncertain market.<\/p>\n

\u201cPharma\u2026 again showcased its unreliability as a defensive\u201d play, Asad Haider, head of U.S. healthcare research and sector strategist at Goldman Sachs, wrote in a Monday note.<\/p>\n

Aside from
\n Novo Nordisk
\n (NVO) and
\n Eli Lilly
\n (LLY), whose new obesity medicines have captured the imaginations of investors and\u00a0boosted their valuations to stratospheric levels, investors seem uninspired by the strategies of the executives leading the big pharma companies. Conditions are unfavorable for the sector.<\/p>\n

The new Medicare drug-price negotiation program will shorten the number of years in which drugmakers can freely set prices on medicines for older Americans, while opposition on antitrust grounds could make mergers more difficult. At the same time, high interest rates have made drug companies\u2019 dividends less attractive.<\/p>\n

Meanwhile, the underlying challenges of the pharmaceutical business aren\u2019t going away. Companies like
\n Pfizer
\n (PFE), which set a new 52-week low on Friday, are preparing for a wave of patent expirations in the coming years that will allow other drugmakers to make some of their key medicines. Bristol and Merck are also facing patent expirations.<\/p>\n

\u201cMuch progress needed with respect to corporate strategy among the Pharma peer group as drug price negotiations over the next year place further pressure on the space while management teams must solve for how to best position their respective businesses between R&D and external business development,\u201d
\n Mizuho
\n healthcare equity strategist Jared Holz wrote in an email to investors on Monday morning.<\/p>\n

Investors\u2019 sour mood could spell trouble for the rest of the pharma pack, many of whom report earnings this week.
\n Pfizer
\n reports on Tuesday, followed by
\n GSK
\n (
\n GSK
\n ) on Wednesday and both Lilly and Novo on Thursday. Also reporting this week are some of the large-cap biotechs, which have been hit by similar dynamics.
\n Amgen
\n \u2018s (AMGN) results arrive on Tuesday, while
\n Regeneron Pharmaceuticals
\n (REGN) and
\n Moderna
\n (MRNA) will report on Thursday.<\/p>\n

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Investors have been hating what drugmakers have to say about their financial results and their corporate strategies. When Bristol Myers Squibb (ticker: BMY) reported its third-quarter earnings on Thursday, shares ended the day down 3.6%, and fell another 2% on Friday. AbbVie stock (ABBV) fell 6.3% on Friday after that company reported earnings. Merck (MRK) […]<\/p>\n","protected":false},"author":1,"featured_media":78753,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-78752","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"\nDrug Stocks Keep Falling on Earnings. It Could Be a Long Week. | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Investors have been hating what drugmakers have to say about their financial results and their corporate strategies. When Bristol Myers Squibb (ticker:\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=78752\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week. | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Investors have been hating what drugmakers have to say about their financial results and their corporate strategies. When Bristol Myers Squibb (ticker:\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=78752\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-31T05:48:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-31T05:48:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/10\/1698731322_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=78752#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=78752\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.\",\"datePublished\":\"2023-10-31T05:48:40+00:00\",\"dateModified\":\"2023-10-31T05:48:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=78752\"},\"wordCount\":576,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=78752#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=78752\",\"url\":\"https:\/\/ifintechworld.com\/?p=78752\",\"name\":\"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week. | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-10-31T05:48:40+00:00\",\"dateModified\":\"2023-10-31T05:48:45+00:00\",\"description\":\"Investors have been hating what drugmakers have to say about their financial results and their corporate strategies. When Bristol Myers Squibb (ticker:\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=78752#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=78752\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=78752#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week. | iFintechWorld","description":"Investors have been hating what drugmakers have to say about their financial results and their corporate strategies. When Bristol Myers Squibb (ticker:","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=78752","og_locale":"en_US","og_type":"article","og_title":"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week. | iFintechWorld","og_description":"Investors have been hating what drugmakers have to say about their financial results and their corporate strategies. When Bristol Myers Squibb (ticker:","og_url":"https:\/\/ifintechworld.com\/?p=78752","og_site_name":"iFintechWorld","article_published_time":"2023-10-31T05:48:40+00:00","article_modified_time":"2023-10-31T05:48:45+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/10\/1698731322_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=78752#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=78752"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.","datePublished":"2023-10-31T05:48:40+00:00","dateModified":"2023-10-31T05:48:45+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=78752"},"wordCount":576,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=78752#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=78752","url":"https:\/\/ifintechworld.com\/?p=78752","name":"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week. | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-10-31T05:48:40+00:00","dateModified":"2023-10-31T05:48:45+00:00","description":"Investors have been hating what drugmakers have to say about their financial results and their corporate strategies. When Bristol Myers Squibb (ticker:","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=78752#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=78752"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=78752#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Drug Stocks Keep Falling on Earnings. It Could Be a Long Week."}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/78752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78752"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/78752\/revisions"}],"predecessor-version":[{"id":78754,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/78752\/revisions\/78754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/78753"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}